Company: PFSA
Filing Date: 2025-05-15
Form Type: 424B3
Source: 0001213900-25-044417
Chunk: 171

Company: Profusa, Inc.
Filing Date: 2025-05-15
Form: 424B3
Chunk 171
---
 proxy statement/prospectus, NorthView’s stockholders should consider these interests. The exercise of NorthView’s directors’ and officers’ discretion in agreeing to changes or waivers in the terms of the Transactions may result in a conflict of interest when determining whether such changes to the terms of the Transactions or waivers of conditions are appropriate and in NorthView’s stockholders’ best interest. In the period leading up to Closing, events may occur that, pursuant to the Merger Agreement, would require NorthView to agree to amend the Merger Agreement, to consent to certain actions taken by Profusa or to waive rights that NorthView is entitled to under, or conditions of, the Merger Agreement. Such events could arise because of a request by Profusa to undertake actions that would otherwise be prohibited by the terms of the Merger Agreement or the occurrence of other events that would have a material adverse effect on Profusa’s business and would entitle NorthView to terminate the Merger Agreement. In any of such circumstances, it would be at NorthView’s discretion, acting through the NorthView Board, to grant its consent or waive those rights or conditions. The existence of the financial and personal interests of the directors described in the preceding risk factors (and described elsewhere in this proxy statement/prospectus) may result in a conflict of interest on the part of one or more of the directors between what he, she or they may believe is best for NorthView and what he, she or they may believe is best for himself, herself or themselves in determining whether or not to take the requested action. As of the date of this proxy statement/prospectus, NorthView does not believe there will be any material changes or waivers that NorthView’s directors and officers would be likely to make after the mailing of this proxy statement/prospectus. While certain changes could be made without further stockholder approval, NorthView will circulate a new or amended proxy statement/prospectus or supplement thereto if changes to the terms of the Transactions that would have a material impact on its stockholders are required prior to the vote on the Business Combination Proposal. If NorthView is unable to complete the Transactions or another initial business combination before June 22, 2025 , or such later date pursuant to our charter, NorthView will cease all operations except for the purpose of winding up, redeeming 100% of the outstanding public shares and, subject to the approval of its remaining stockholders and the NorthView Board, dissolving and liquidating. In such event, third parties may bring